Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Oncology
Disease Category: Endometrial Cancer
Trial Information
PHII-89; NCI #7713: A Phase II Study of Sunitinib Malate in Recurrent or Metastatic Endometrial Carcinoma
You have been asked to participate in this research study because have endometrial cancer (cancer of the uterus) that is either recurrent (has returned after initial treatment) or has metastasized (spread beyond the uterus). The purpose of this research study is to evaluate the safety and effectiveness of the investigational agent sunitinib malate on advanced or metastatic endometrial cancer. Your treatment on this study is expected to last for as long as your disease is not growing and you are not having any unmanageable side effects. After your treatment on this study is over, your medical condition will continue to be followed indefinitely.
Patient Inclusion/Exclusion Criteria:
- See http://clinicaltrials.coh.org for additional information.
City of Hope
1500 East Duarte Road
Duarte, CA 91010-3000
Phone: 866-896-HOPE (4673)
View Google Map
Research Center Information: City of Hope
DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the
clinical trials industry. The information provided in this service is designed
to help patients find clinical trials that may be of interest to them, and to
help patients contact the centers conducting the research. CenterWatch is
neither promoting this research nor involved in conducting any of these
trials.
